Candel Therapeutics' Lead Candidate CAN-2409 Battles Lung, Pancreatic, and Prostate Cancers
June 7, 2024 — Candel Therapeutics' lead candidate CAN-2409 offers a new multimodal biological approach to immunotherapy, showing promising results in improving overall survival rates in non-small cell lung cancer and pancreatic cancer. This innovative treatment provides hope for cancer patients and has the potential to significantly impact the landscape of cancer treatment.